Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference

Abstract

Patients with indication for anticoagulation may prefer treatment with a vitamin K antagonist (VKA) or non-vitamin K antagonist oral anticoagulant (NOAC). A questionnaire may help to identify the preference of patients for one of the two types of oral anticoagulants and to develop a score for the recommendation to continue or to change the anticoagulant. A score was developed using a questionnaire containing biographic data and eight statements on attitudes on anticoagulation and was derived to trigger continuation or change the type of anticoagulant by defining ranges of terms and weighting of the significant statements identified by logistic regression analysis. Participating patients received either anticoagulation with VKA (group 1, n = 690), were transferred from VKA to NOAC (group 2, n = 158), received NOAC de novo (group 3, n = 137) or were transferred from NOAC to VKA (group 4, n = 19). Four statements were significantly (p values between 0.0347 and < 0.0001) associated with recommendations to maintain or to change the type of anticoagulant for patients in groups 1, 2, or 3 with predictive values of c = 0.83 between groups 1 and 2 and c = 0.71 between groups 1 and 3. From the total number of replies to the statements a score of three grades and two strengths (A = strong, B = moderate) was derived for the recommendations. This tool supports recommendations as to continue or to change the presently used type of oral anticoagulant based on the identification of patients' preferences.

Keywords

anticoagulation - vitamin K antagonist - new oral anticoagulant - preference - questionnaire - score - recommendation

• References

• 1 Falck-Ytter Y, Francis CW, Johanson NA , et al; American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e278S-e325S
• 2 Vílchez JA, Gallego P, Lip GY. Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf 2014; 5 (1) 8-20
• 3 Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123 (7) 638-645.e4
• 4 Hong C, Kim S, Curnew G, Schulman S, Pullenayegum E, Holbrook A. Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. J Popul Ther Clin Pharmacol 2013; 20 (3) e229-e237
• 5 Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999; 318 (7194) 1324-1327
• 6 Thomson RG, Eccles MP, Steen IN , et al. A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial. Qual Saf Health Care 2007; 16 (3) 216-223
• 7 Zeber JE, Manias E, Williams AF , et al; ISPOR Medication Adherence Good Research Practices Working Group. A systematic literature review of psychosocial and behavioral factors associated with initial medication adherence: a report of the ISPOR medication adherence & persistence special interest group. Value Health 2013; 16 (5) 891-900
• 8 Camm AJ, Lip GY, De Caterina R , et al; ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14 (10) 1385-1413
• 9 Anderson JL, Halperin JL, Albert NM , et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61 (18) 1935-1944
• 10 MacLean S, Mulla S, Akl EA , et al; American College of Chest Physicians. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e1S-e23S
• 11 National-Institute-for-Health-and-Care-Excellence. Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180) 2014. Available at: http://guidance.nice.org.uk/CG180 . Accessed February 6, 2015
• 12 Farin E, Meder M. Personality and the physician-patient relationship as predictors of quality of life of cardiac patients after rehabilitation. Health Qual Life Outcomes 2010; 8: 100
• 13 Gabbidon J, Brohan E, Clement S, Henderson RC, Thornicroft G ; MIRIAD Study Group. The development and validation of the Questionnaire on Anticipated Discrimination (QUAD). BMC Psychiatry 2013; 13 (1) 297
• 14 Moia M, Mantovani LG, Carpenedo M , et al. Patient preferences and willingness to pay for different options of anticoagulant therapy. Intern Emerg Med 2013; 8 (3) 237-243
• 15 Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. Semin Thromb Hemost 2014; 40 (1) 121-128
• 16 Elewa HF, DeRemer CE, Keller K, Gujral J, Joshua TV. Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. J Thromb Thrombolysis 2014; 38 (1) 115-120
• 17 Zolfaghari S, Harenberg J, Knäble H , et al. Investigation on motivation of patients to participate in clinical studies with new oral anticoagulants (abstract). Haemostaseologie 2013; 33 (1) 5-22
• 18 Crawford B, Stanford RH, Wong AY, Dalal AA, Bayliss MS. Development of a questionnaire to assess experience and preference of intranasal corticosteroids in patients with allergic rhinitis. Patient Relat Outcome Meas 2011; 2: 119-126
• 19 Franke GH. [Possibilities of computer-assisted administration of the revised Freiburg Personality Inventory. 2 experimental studies]. Zeitschrift fur experimentelle Psychologie. Organ der Deutschen Gesellschaft fur Psychologie 1997; 44 (2) 332-356
• 20 Forgays DG, Forgays DK, Spielberger CD. Factor structure of the State-Trait Anger Expression Inventory. J Pers Assess 1997; 69 (3) 497-507
• 21 Fisher PL, Durham RC. Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol Med 1999; 29 (6) 1425-1434
• 22 Völler H, Taborski U, Dovifat C , et al. ProTime self-management yielding improvement of fluency and quality of life. Thromb Haemost 2007; 98 (4) 889-895
• 23 Oechsner W, Geiler S, Huber-Lang M. The impact of a dedicated training program for oral examiners at a medical school in Germany: a survey among participants from operative and non-operative disciplines. Patient Saf Surg 2013; 7 (1) 22
• 24 EvaSys Available at: http://www.evasys.de/startseite.html . Accessed May 28, 2014
• 25 Skogen JC, Bøe T, Knudsen AK, Hysing M. Psychometric properties and concurrent validity of the CRAFFT among Norwegian adolescents. Ung@hordaland, a population-based study. Addict Behav 2013; 38 (10) 2500-2505
• 26 Guyatt GH, Norris SL, Schulman S , et al; American College of Chest Physicians. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): 53S-70S
• 27 Eikelboom JW, Connolly SJ, Brueckmann M , et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13) 1206-1214
• 28 Lu Y, Branstad R, Karim RM, Asinger RW. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. J Clin Pharm Ther 2014; 39 (6) 628-636
• 29 Chenot JF, Hua TD, Abu Abed M , et al. Safety relevant knowledge of orally anticoagulated patients without self-monitoring: a baseline survey in primary care. BMC Fam Pract 2014; 15: 104
• 30 Ghijben P, Lancsar E, Zavarsek S. Preferences for oral anticoagulants in atrial fibrillation: a best-best discrete choice experiment. Pharmacoeconomics 2014; 32 (11) 1115-1127
• 31 Chorão P, Pereira AM, Fonseca JA. Inhaler devices in asthma and COPD—an assessment of inhaler technique and patient preferences. Respir Med 2014; 108 (7) 968-975
• 32 Sylwestrzak G, Liu J, Stephenson JJ, Ruggieri AP, DeVries A. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits 2014; 7 (2) 71-81
• 33 Demary W, Schwenke H, Rockwitz K , et al. Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience. Patient Prefer Adherence 2014; 8: 1061-1071
• 34 Tinelli M, Nikoloski Z, Kumpunen S , et al. Decision-making criteria among European patients: exploring patient preferences for primary care services. Eur J Public Health 2014;
• 35 Devereaux PJ, Anderson DR, Gardner MJ , et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323 (7323) 1218-1222
• 36 Michal M, Prochaska JH, Ullmann A , et al. Relevance of depression for anticoagulation management in a routine medical care setting: results from the ThrombEVAL study program. J Thromb Haemost 2014; 12 (12) 2024-2033
• 37 Prochaska JH, Coldewey M, Göbel S , et al; for the thrombEVAL Study Group. Evaluation of oral anticoagulation therapy: rationale and design of the thrombEVAL study programme. Eur J Prev Cardiol 2014;